VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy
The designation covers VCA-894A, Vanda’s investigational treatment for Charcot-Marie-Tooth disease type 2S.
Read the full articleYou might also wanna read
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) ve
FDA·2mo ago
FDA Clears NIH-Supported Gene Therapy MMA-101 for First Human Trial in Rare Metabolic Disorder
MMA-101, an NIH-supported gene therapy for a rare metabolic disorder, has received FDA clearance to begin clinical testing.
ncats.nih.gov·11d agoPediatric Movement Disorders of Unknown Etiology in Vietnam (VPeMD)
Conditions : Movement Disorders in Children; Neuro Developmental Delay; Neurogenetic Disorders Interventions : Diagnostic Test: Whole-Exome
NIH and NIDCR Advance First-in-Human Trial for Ultra-Rare Jansen's Disease Therapy
NIDCR prepares a first-in-human trial for Jansen’s disease, advancing a potential therapy for this ultra-rare skeletal disorder through NIH
FDA reverses course on Regenxbio’s childhood gene therapy after rejection
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four
statnews.com·18d agoFDA Accepts Immunome’s NDA for Varegacestat in Desmoid Tumors, Setting Up an April 2027 Decision
Key Takeaways The FDA has accepted Immunome’s New Drug Application (NDA) for varegacestat in adults with desmoid tumors, with a PDUFA target
Comments
Sign in to join the conversation.
No comments yet. Be the first.